Diagnosing celiac disease in children without a biopsy: what the ESPGHAN guideline requires

Short answer

ESPGHAN’s 2020 pediatric guideline sets these steps for diagnosing a child without a biopsy, and says children with lower positive results should have biopsies1, 2:

  1. Positive results go to a pediatric gastroenterologist or other specialist3.
  2. TGA-IgA, the tTG antibody test, is at least 10 times the upper limit of normal, measured on an assay the guideline accepts1, 4, 27.
  3. Endomysial antibodies (EMA-IgA) test positive in a second blood sample1, 5.
  4. The family agrees, after a shared decision with the parents1, 6.

Published by Gluten Verdict · updated · 8 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Yellow school backpack hung on a chair beside a folded letter on a kitchen table

Key points

  • The 10-times level is not a rule of thumb: ESPGHAN limits it to antibody tests with a calibrator curve-based calculation that have the 10× upper-limit value within their measurement range4.
  • The 2020 guideline drops two 2012 requirements: HLA typing and symptoms are not obligatory criteria7, 8, 9.
  • US guidance is less settled: the American College of Gastroenterology wrote that solid information about non-biopsy diagnosis in the United States was not available yet10.
  • In a survey of North American pediatric gastroenterology providers published in 2024, 47.5% of respondents also accepted serology-based criteria in certain circumstances; the response rate was 10.8%11, 12.
  • NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing13.

Why do children have their own route?

NIDDK says doctors typically diagnose celiac disease with blood tests and biopsies of the small intestine14. ESPGHAN’s 2012 guidelines allowed serology-based (blood test) diagnosis in selected cases, omitting the necessity of histopathology (biopsy)15.

The reasoning was that gut damage of the typical kind (Marsh 2 or 3 changes) was nearly always present in children with very high antibody levels16. ESPGHAN notes that adult guidelines published later did not give the option17.

Symptoms alone do not decide it either: NIDDK says celiac disease isn’t diagnosed based on symptoms alone, because some symptoms resemble those of other digestive disorders18.

What the 2020 ESPGHAN guideline requires

ESPGHAN is the European society for pediatric gastroenterology, hepatology and nutrition. Its 2020 guideline sets out these steps (the numbering is ours):

  1. Start with total IgA and TGA-IgA. These are the first tests in a child with suspected celiac disease; when total IgA is low, an IgG-based test is the second step19.
  2. Refer. Patients with positive results should be referred to a pediatric gastroenterologist or other specialist3.
  3. Reach the 10-times level. ESPGHAN recommends that, for a diagnosis without biopsies, TGA-IgA of at least 10 times the upper limit of normal (10× ULN) be obligatory, measured with a test that uses a calibrator curve and has the 10× ULN value within its measurement range4.
  4. Confirm in a second sample. The diagnosis should be confirmed by a positive EMA-IgA test in a second blood sample5.
  5. Agree with the family. The no-biopsy diagnosis may be applied when the family agrees1; ESPGHAN says the choice whether to biopsy should be made through shared decision-making with the parents and, if appropriate, the child6.

In the studies ESPGHAN reviewed, 28 of 30 datasets evaluating the 10× cut-off reported a positive predictive value (PPV, how often a positive result proved right) above 95%, and 21 reported above 99%20.

The guideline’s own conclusion is conditional: celiac disease diagnosis can be accurately established with or without duodenal biopsies if the given recommendations are followed21.

Why a second blood sample?

ESPGHAN says the no-biopsy recommendation rests on a second serum sample, taken for EMA-IgA on a separate occasion while the child is on a gluten-containing diet22. It states the aim as avoiding mislabelling of samples or technical errors and confirming celiac autoimmunity with another test assay with high specificity23.

It also says that, because of variability between laboratories and between tests, positive TGA-IgA levels below 10× ULN are prone to technical error and not sufficient for the no-biopsy approach24.

What changed from the 2012 criteria

The 2012 ESPGHAN guideline required all five of the conditions in the table’s middle column for the no-biopsy approach25.

The 2012 criteria and the 2020 guideline, as ESPGHAN states them
Condition2012 criteria2020 guideline
SymptomsSymptoms suggestive of celiac disease (particularly malabsorption)8Not obligatory7; the no-biopsy route is conditionally recommended for children without symptoms, using the same criteria6
HLA DQ2/DQ8 typingPositive HLA risk alleles9Not required when TGA-IgA is at least 10× ULN with a positive EMA-IgA26
TGA-IgA levelAt least 10 times the upper limit of normal27At least 10× ULN is obligatory, on an assay with a calibrator curve4
EMA-IgAPositive in a second serum sample28Positive in a second blood sample5
FamilyPatients/parents who understand the diagnosis and are committed to a gluten-free diet29The family agrees; the decision is shared with the parents1, 6

Charity pages do not all describe the 2020 conditions. Gluten Intolerance Group’s page on testing children (its web address dates it to 2019) says a small intestine endoscopy is generally needed to confirm celiac disease, though it may not be recommended for very young children30, and adds that positive screening tests in combination with positive genetic tests and symptoms may be considered sufficient to make a diagnosis31. That is a different set of conditions from the 2020 guideline’s, and which one applies to a child is the pediatric gastroenterologist’s call.

Where the US position stands

ESPGHAN is a European society, so the US picture needs its own sources. The American College of Gastroenterology’s 2023 guideline calls the biopsy-free approach a reasonable alternative to the standard approach in selected children32. It names one limitation, which includes the absence of standardization of tTG assays and the real risk of misdiagnosis without following the strict ESPGHAN criteria in clinical practice33. It also says solid information about non-biopsy diagnosis in the United States was not available yet10.

A 2024 paper reports a survey of North American pediatric gastroenterology providers, run from September 2021 to January 202234 and developed by a subcommittee of a NASPGHAN special interest group35. All respondents used endoscopy with biopsy, and 47.5% (132 of 278) also accepted non-biopsy, serology-based criteria in certain circumstances11. The response rate was 10.8%12, so the figure describes who answered, not every clinician. The authors write that further studies are needed in North America on the accuracy of serology-based diagnosis36.

NASPGHAN’s own 2016 clinical report on gluten-related disorders says it discusses the initial and subsequent tests needed to confirm the diagnosis37, and that it is not possible to tell these disorders apart on clinical grounds alone38. We could read only its abstract, so we do not report what it says about skipping a biopsy39.

When the no-biopsy route does not apply directly

  • Positive but below 10× ULN. ESPGHAN says children with positive TGA-IgA at lower titers should undergo biopsies to decrease the risk of a false positive diagnosis2, taking at least 4 biopsies from the distal duodenum and at least 1 from the duodenal bulb40.
  • Low or absent total IgA. ESPGHAN recommends against omitting biopsies in IgA-deficient children whose positive results come from IgG-based tests41.
  • A borderline result. ESPGHAN’s algorithm says to confirm sufficient gluten intake and consider re-testing TGA-IgA and EMA42.
  • Blood and biopsy results that disagree. ESPGHAN says re-cutting of the biopsies and/or a second opinion from an experienced pathologist should be requested43.

ESPGHAN notes that its question on children without symptoms did not address patients with coexisting type 1 diabetes, because studies with a large number of such celiac cases were not in its literature search44.

What a biopsy adds, and what skipping it gives up

ESPGHAN does not treat the biopsy as a perfect reference: it states that variability between observers in grading small-bowel histopathology is high, so histopathology cannot serve as the sole reference standard45.

On what skipping the endoscopy could miss, the guideline states there is no evidence to support that relevant diagnoses are missed when upper endoscopy with biopsies is omitted to diagnose celiac disease46. It adds that, in general, celiac patients should be monitored while on a gluten-free diet so that no additional gastrointestinal issues are missed47.

How this differs for adults

For adults, the American College of Gastroenterology gives the main concern about the approach as the relative paucity of data on the positive predictive value of serology in adults, compared with the larger body of literature in children48. It cites one multicenter international study of adults in which a 10-fold or greater elevation of tTG IgA had a positive predictive value of 95%49, and says that, given the life-long treatment implications of a gluten-free diet, this may be unacceptably low50.

Coeliac UK, a UK charity, describes both groups. For children it says a biopsy may not be necessary if antibody levels are ten times the upper limit of normal followed by a second positive blood test, in discussion with a pediatric gastroenterologist (or a pediatrician with a special interest in gastroenterology), the parents or carers and the child, where appropriate51. For adults it says around 20-30% of adults with symptoms associated with undiagnosed coeliac disease have antibody levels that high, so that they can be diagnosed without endoscopy and biopsy52. That is UK charity guidance, not a US rule.

Gluten Intolerance Group’s article on adults says an intestinal biopsy is the current “gold standard” for diagnosing adults53, and that the suggestion to avoid biopsies has not been adopted for the standards in the diagnosis of celiac disease at this time, though it calls the idea promising for the future54.

Topics the guideline’s conditions raise for the pediatric gastroenterologist

This is not advice about a particular child, and the clinician decides. Each topic follows from a condition the sources above set out.

  • Which antibody test measured the result, and was it at least 10 times that test’s upper limit of normal? ESPGHAN limits the 10× threshold to tests with a calibrator curve-based calculation that have the 10× value within their measurement range4.
  • Was total IgA checked? ESPGHAN recommends testing total IgA alongside TGA-IgA19, and recommends against omitting biopsies in IgA-deficient children with positive IgG-based tests41.
  • Has EMA-IgA been checked on a second blood sample, taken while the child eats gluten? ESPGHAN’s recommendation rests on exactly that22.
  • Is a diagnosis without biopsy being offered, and is the family’s choice part of the decision? ESPGHAN says it may be applied if the family agrees1.
  • Which criteria does the practice follow, the 2012 ones that required HLA typing and symptoms9, 8, or the 2020 guideline, where neither is obligatory7?

Keeping gluten in the diet until testing is done

NIDDK says doctors don’t recommend starting a gluten-free diet before diagnostic testing, because a gluten-free diet can affect test results13. Gluten Intolerance Group’s page on testing children says not to remove gluten from the child’s diet before testing55.

Coeliac UK says to continue eating gluten until all the required tests, blood tests and biopsy where necessary, are done56, and that guidelines recommend eating some gluten in more than one meal every day for at least six weeks before testing57.

ESPGHAN’s algorithm notes that a diagnosis with or without a biopsy confirms the need for a lifelong gluten-free diet, and that re-evaluation after the diet is introduced would need prolonged re-exposure to gluten with a series of further investigations58.

Questions people ask

Can celiac disease be diagnosed in a child with only a blood test?

ESPGHAN’s 2020 guideline says the no-biopsy diagnosis may be applied if TGA-IgA is at least 10 times the upper limit of normal, EMA-IgA is positive in a second blood sample and the family agrees1. NIDDK describes the usual route as blood tests and biopsies of the small intestine14.

Is a genetic (HLA) test needed first?

ESPGHAN’s 2020 guideline says HLA typing is not required in patients with high TGA-IgA (at least 10× ULN) and positive EMA-IgA26. Its 2012 criteria had required positive HLA risk alleles9.

What if the tTG result is positive but under 10 times the limit?

ESPGHAN says children with positive TGA-IgA at lower titers should undergo biopsies2, because positive levels below 10× ULN are prone to technical error and not sufficient for the no-biopsy approach24.

Does the guideline apply to children without symptoms?

ESPGHAN gives a conditional recommendation that celiac disease can be diagnosed without biopsies in children without symptoms, using the same criteria6. It adds that the positive predictive value of a high TGA-IgA may be lower in these children and needs to be considered in the decision59.

Do US pediatric gastroenterologists ever diagnose without a biopsy?

In a survey of North American pediatric gastroenterology providers published in 2024, all respondents used endoscopy with biopsy and 47.5% also accepted non-biopsy, serology-based criteria in certain circumstances11; the response rate was 10.8%12. The American College of Gastroenterology said solid information about non-biopsy diagnosis in the United States was not available yet10.

More in Celiac diagnosis, testing and gluten sensitivity

Sources